Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
•
Tocilizumab
•
GCA
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
Related Questions
How would you approach management of nodular scleritis in the setting of suspected GCA?
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
Do you utilize temporal artery ultrasound in your practice?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
What features on CTA/MRA are most helpful for differentiating large vessel vasculitis from atherosclerosis?
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
How would you approach management of a patient with mixed cryoglobulinemic vasculitis with predominant skin involvement and no major organ involvement?
How soon after starting treatment would you repeat imaging in patients with Takayasu to monitor response and ensure you have the correct diagnosis?
How do you interpret a negative ANCA and a low positive PR3?
